Immunotherapy combo shows promise for Post-Transplant blood cancers
NCT ID NCT03600155
First seen Feb 23, 2026 · Last updated Apr 29, 2026 · Updated 8 times
Summary
This study tested two immunotherapy drugs, nivolumab and ipilimumab, in 29 people whose acute myeloid leukemia or myelodysplastic syndrome returned or did not respond after a donor stem cell transplant. The goal was to find the safest dose and see if the drugs could help the immune system fight the cancer. The study is complete, and results help guide future treatment approaches.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.